ARIAD reports net income of $13.9 million for third quarter 2011 ARIAD Pharmaceuticals, Inc. today reported economic results for the 3rd one fourth of 2011 and supplied an revise on its corporate developments canada pharmacy . Berger, M.D., chairman and chief executive officer. At the same time, AP26113, our exclusive, investigational dual-inhibitor of ALK and EGFR, offers advanced in to the clinic, and we think that it may address a significant unmet medical want in two clinically important, molecularly defined subgroups of individuals with non-little cell lung cancer.
FDA. THE BUSINESS also disclosed the departure of Dr. Robert Gundel, Chief Scientific Officer, from ARIUS.. ARIUS announces allowance folks patent for lead anti-cancer antibody ARIUS Research Inc., provides announced that the Company has received notice from america Patent and Trademark Office a key patent because of its lead anti-CD44 drug candidate will issue on August 7th, 2007, mainly because US Patent # 7 7,252,821. This pivotal patent covers the ARH460-16-2 antibody itself, and also the use of the antibody in the treating breast cancers. ARIUS now has 16 issued and allowed patents covering its antibody programs and discovery platform and over 150 patents pending.